A Case Study of Roche’s Drug Trials in China
Introduction
In business we must evaluate decisions along ethical lines and we must recognize that, for the long-term benefit of society, we cannot always make these decisions based simply upon a profit motive. The following case exemplifies the complexities inherent in business decisions. The case examined addresses whether it is worth doing something ethically questionable for the sake of a justified end.
In 2010, the pharmaceutical company Roche came under fire from Traidos Bank, the Berne Declaration, Greenpeace, and other critics for its policy of testing an organ transplantation drug called CellCept in China. CellCept is a drug designed to “prevent the rejection of transplanted organs”, and has been used successfully in many countries around the world. In order to market CellCept in China, Roche needed regulatory approval that would only be given after the completion of drug trials in China. Requirements included documenting the optimal drug dosage and checking for ethnic or constitutional differences in Chinese patients. Criticism levied against Roche centered upon organ sourcing problems in China. In most countries, free and informed consent must be given by donors in order for their organs to be used. In China, however, the circumstances of organ removal were often unknown or unknowable. Critics argued that Roche, by participating in the organ transplant market in China, was party to a corrupt system that violated the consent rights of prisoners and other vulnerable donor populations. These critics claimed that Roche should use its power to enforce “a much clearer position on the origin of transplanted organs.” Even though Roche admitted that some percentage of its operations used organs taken without consent, the company countered by claiming that it did not have the capability to discover the origin of transplants. Furthermore, Roche explained that it was not directly involved in the